Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale André(Innate Pharma (France)), Caroline Denis(Innate Pharma (France)), Caroline Soulas(Innate Pharma (France)), Clarisse Bourbon-Caillet(Innate Pharma (France)), Julie Lopez(Innate Pharma (France)), Thomas Arnoux(Innate Pharma (France)), Mathieu Bléry(Innate Pharma (France)), Cécile Bonnafous(Innate Pharma (France)), Laurent Gauthier(Innate Pharma (France)), Ariane Morel(Innate Pharma (France)), Benjamín Rossi(Innate Pharma (France)), Romain Remark(Innate Pharma (France)), Violette Breso(Innate Pharma (France)), Elodie Bonnet(Innate Pharma (France)), Guillaume Habif(Innate Pharma (France)), Sophie Guia(Centre d’Immunologie de Marseille-Luminy), Ana I. Lalanne(Institut Curie), Caroline Hoffmann(Institut Curie), Olivier Lantz(Inserm), Jérôme Fayette(Centre Léon Bérard), Agnès Boyer-Chammard(Innate Pharma (France)), Robert Zerbib(Innate Pharma (France)), P. Dodion(Innate Pharma (France)), Hormas Ghadially, Maria Jure‐Kunkel, Yannis Morel(Innate Pharma (France)), Ronald Herbst, Émilie Narni-Mancinelli(Centre d’Immunologie de Marseille-Luminy), Roger B. Cohen(Abramson Cancer Center), Éric Vivier(Aix-Marseille Université)
Cited by 1,175Open Access
Abstract
T cell function in combination with PD-x axis blockade. Monalizumab also stimulated NK cell activity against antibody-coated target cells. Interim results of a phase II trial of monalizumab plus cetuximab in previously treated squamous cell carcinoma of the head and neck showed a 31% objective response rate. Most common adverse events were fatigue (17%), pyrexia (13%), and headache (10%). NKG2A targeting with monalizumab is thus a novel checkpoint inhibitory mechanism promoting anti-tumor immunity by enhancing the activity of both T and NK cells, which may complement first-generation immunotherapies against cancer.